

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 48524

Manuscript Type: ORIGINAL ARTICLE

Retrospective Study

Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis

Lee JI *et al.* CAP in liver stiffness of NASH

Jung Il Lee, Hyun Woong Lee, Kwan Sik Lee

Abstract

Match Overview

1	Crossref 38 words "Posters (Abstracts 301-2389)", Hepatology, 2018	1%
2	Crossref 15 words J Foucher. "Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study", Gut, 3/1/2006	1%
3	Crossref 13 words Salvatore Petta, Vincent Wai-Sun Wong, Calogero Cammà, Jean-Baptiste Hiriart et al. "Improved noninvasive prediction	<1%
4	Crossref 13 words Shira Zelber-Sagi, Dorit Nitzan-Kaluski, Rebecca Goldsmith, Muriel Webb et al. "Role of leisure-time physical activity in ...	<1%
5	Internet 11 words crawled on 28-Nov-2018. aasldpubs.onlinelibrary.wiley.com	<1%
6	Internet 11 words crawled on 13-Nov-2017 e-sciencecentral.org	<1%
7	Internet 10 words crawled on 29-Jun-2017 www.nice.org.uk	<1%



All

Images

Videos

翻译成中文

关闭取词

39,600 Results

Any time ▾

Transient elastography (FibroScan®) with controlled ...

www.ncbi.nlm.nih.gov › ... › v.22(32); 2016 Aug 28

Aug 28, 2016 · Transient elastography (TE) with **controlled attenuation parameter** (CAP) is a fast, reliable, repeatable non-invasive method for the assessment of liver steatosis and **fibrosis**. TE with CAP may be used to diagnose and monitor patients with NAFLD. TE with CAP is a favorable means of excluding advanced **fibrosis**.

Cited by: 26

Author: Ivana Mikolasevic, Lidija Orlic, Neven Fra...

Publish Year: 2016

Improved noninvasive prediction of liver fibrosis by liver ...

<https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.28843>

Sep 17, 2016 · Liver stiffness measurement (LSM) frequently overestimates the **severity** of liver **fibrosis** in **nonalcoholic fatty liver** disease (NAFLD). **Controlled attenuation parameter** (CAP) is a new **parameter** provided by the same machine used for LSM and associated with both **steatosis** and body mass index, the two factors mostly affecting LSM performance in NAFLD.

Cited by: 71

Author: Salvatore Petta, Vincent Wai-Sun Wong, ...

Publish Year: 2017

Controlled attenuation parameter for the diagnosis of ...

<https://onlinelibrary.wiley.com/doi/abs/10.1111/jgh.13219>

Oct 29, 2015 · **Controlled attenuation parameter** (CAP) evaluated with transient elastography (FibroScan) is a recent method for non-invasive assessment of steatosis. ... Diagnosis and Evaluation of **Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis**, ... , Improved noninvasive **prediction** of liver **fibrosis** by liver stiffness measurement in patients ...

Cited by: 61

Author: de Lédinghen, Wong GI, Vergniol J, Chan...

Publish Year: 2016

Diagnostic value of controlled attenuation parameter for ...

www.ncbi.nlm.nih.gov › ... › v.20(30); 2014 Aug 14

Aug 14, 2014 · Relationship between **controlled attenuation parameter** index and hepatic steatosis stage, inflammation degree, and **fibrosis** degree Diagnostic **values** of CAP for hepatic steatosis The areas under the curves (AUCs) for CAP at stages S1, S2, and S3 were 0.711 (0.592 to 0.870), 0.868 (0.748 to 0.989), and 0.974 (0.922 to 1.026), respectively.

Cited by: 11

Author: Chun-Yan Wang, Wei Lu, Dong-Sheng H...

Publish Year: 2014

Relationship between Serum Cytokeratin-18, Control ...



All

Images

Videos

翻译成中文

关闭取词

38,200 Results

Any time ▾

Accuracy of FibroScan Controlled Attenuation Parameter and ...

[https://www.gastrojournal.org/article/S0016-5085\(19\)30105-2/fulltext](https://www.gastrojournal.org/article/S0016-5085(19)30105-2/fulltext)

We estimated the accuracy of FibroScan vibration-controlled transient elastography **controlled attenuation parameter** (CAP) and liver stiffness measurement (LSMs) in assessing steatosis and **fibrosis** in patients with suspected **nonalcoholic** liver disease (NAFLD).

Cited by: 2

Author: Peter J. Eddowes, Magali Sasso, Michael...

Publish Year: 2019

Diagnostic value of controlled attenuation parameter for ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130870>

Aug 14, 2014 · Diagnostic value of controlled attenuation parameter at three decision points
DISCUSSION In previous studies, approximately 27% to 51% of the **total number** of patients with CHB suffered from **hepatic steatosis** [4 , 5].

Cited by: 12

Author: Chun-Yan Wang, Wei Lu, Dong-Sheng H...

Publish Year: 2014

Accuracy of FibroScan Controlled Attenuation Parameter and ...

<https://www.sciencedirect.com/science/article/pii/S0016508519301052>

Background & Aims. We estimated the accuracy of FibroScan vibration-controlled transient elastography **controlled attenuation parameter** (CAP) and liver stiffness measurement (LSMs) in assessing steatosis and **fibrosis** in patients with suspected **nonalcoholic** liver disease (NAFLD).

Cited by: 2

Author: Peter J. Eddowes, Magali Sasso, Michael...

Publish Year: 2019

[PDF] Accuracy of FibroScan Controlled Attenuation Parameter ...

[https://www.gastrojournal.org/article/S0016-5085\(19\)30105-2/pdf](https://www.gastrojournal.org/article/S0016-5085(19)30105-2/pdf)

measuring **ultrasonic attenuation** of the echo wave, termed the **controlled attenuation parameter** (CAP),^{8,9} which has been compared with **liver biopsy** (LB) in prospective studies with the M probe.^{10–12} Previous studies have demonstrated the limitations of the M probe in patients with an increased skin-to-liver

Improved noninvasive prediction of liver fibrosis by liver ...

<https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.28843>

Sep 17, 2016 · **Controlled attenuation parameter** (CAP) is a new **parameter** provided by the same machine used for LSM and associated with both steatosis and body mass index; the two factors mostly



Accuracy of FibroScan Controlled Attenuation Parameter and ...

[https://www.gastrojournal.org/article/S0016-5085\(19\)30105-2/fulltext](https://www.gastrojournal.org/article/S0016-5085(19)30105-2/fulltext)

We estimated the accuracy of FibroScan vibration-controlled transient elastography controlled attenuation parameter (CAP) and liver stiffness measurement (LSMs) in assessing steatosis and fibrosis in patients with suspected nonalcoholic liver disease (NAFLD).

Cited by: 2 Author: Peter J. Eddowes, Magali Sasso, Michael...

Publish Year: 2019

Accuracy of FibroScan Controlled Attenuation Parameter and ...

<https://www.sciencedirect.com/science/article/pii/S0016508519301052>

Background & Aims. We estimated the accuracy of FibroScan vibration-controlled transient elastography controlled attenuation parameter (CAP) and liver stiffness measurement (LSMs) in assessing steatosis and fibrosis in patients with suspected nonalcoholic liver disease (NAFLD).

Cited by: 2 Author: Peter J. Eddowes, Magali Sasso, Michael...

Publish Year: 2019

Improved noninvasive prediction of liver fibrosis by liver ...

<https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.28843>

Sep 17, 2016 · Controlled attenuation parameter (CAP) is a new parameter provided by the same machine used for LSM and associated with both steatosis and body mass index, the two factors mostly affecting LSM performance in NAFLD. We aimed to determine whether prediction of liver fibrosis by LSM in NAFLD patients is affected by CAP values.

Cited by: 80 Author: Salvatore Petta, Vincent Wai-Sun Wong, ...

Publish Year: 2017

Controlled attenuation parameter for the diagnosis of ...

<https://onlinelibrary.wiley.com/doi/full/10.1111/jgh.13219>

Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease ... especially in patients with non-alcoholic steatohepatitis, and with elevated BMI could be useful for the diagnosis and follow-up of NAFLD patients. ... , Improved noninvasive prediction of liver fibrosis by liver stiffness measurement ...

Cited by: 72 Author: de Lédinghen, Wong GI, Vergniol J, Chan...

Publish Year: 2016

Transient elastography (FibroScan®) with controlled ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997649>

Aug 28, 2016 · Gastrointestinal Non-alcoholic fatty liver disease (NAFLD) patients are at risk of NAFLD-related